TUCSON, Ariz., November 19, 2024 — Critical Path Institute® (C-Path) today announced that its Translational Therapeutics Accelerator (TRxA) program, in partnership with The Leona M. and Harry B. Helmsley Charitable Trust, a new research grant aimed at developing a novel treatment for type 1 diabetes (T1D). This award is made through TRxA’s Bridging Research and Innovation in Drug Development Grants (BRIDGe) program, which is designed to support academic researchers in traversing the drug development valley of death and advancing new cutting-edge therapeutics from the lab to patients. Continue reading
Author Archive: Roxan Olivas
C-Path Announces Gender Equitable Medicines for Parkinson’s Disease (GEM‑PD) Initiative
C-Path expands its worldwide leadership in accelerating drug development in neurology; seeks additional collaborators to broaden impact.Continue reading
C-Path Announces Key Leadership Appointments in Neurodegenerative Disease Research
Dr. Diane Stephenson Promoted to Vice President of Neurology; Dr. Nadine Tatton Welcomed as New Executive Director of CPADContinue reading
C-Path to Lead Comprehensive Task Force Focused on Accelerating Drug Development for Limb-Girdle Muscular Dystrophies
TUCSON, Ariz., September 30, 2024 — Critical Path Institute (C-Path) today announced the formation of a new task force under its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), dedicated to advancing therapeutic development for limb-girdle muscular dystrophies (LGMDs). This initiative brings together leading organizations and experts in a concerted effort to tackle the challenges associated with LGMDs drug development. LGMDs are a group of disorders that affect voluntary muscles, primarily those around the hips and shoulders.Continue reading
C-Path’s Inaugural Global Impact Conference Charts the Future of Drug Development
WASHINGTON, Sept. 12, 2024 — Critical Path Institute (C-Path) successfully concluded its inaugural Global Impact Conference (CGIC) on September 11, 2024, at the Washington Marriott at Metro Center in Washington, D.C. This landmark event brought together industry leaders, regulatory agencies, academic experts, and patient advocacy groups, all dedicated to advancing drug development and regulatory science for rare diseases. Continue reading
FDA Issues ‘Letter of Support’ Encouraging Use of Synuclein-based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson’s and Related Diseases
- U.S. regulatory agency recognizes potential of alpha-synuclein seed amplification assay (αSyn-SAA) to accelerate clear outcomes in drugmakers’ trials
- Letter is latest milestone in the journey of the biomarker, discovered in 2023, to transform drug development focused on synuclein pathology — a biological hallmark of Parkinson’s, Dementia with Lewy Bodies and related neurodegenerative conditions
- FDA notes critical role of the Parkinson’s Progression Markers Initiative in generating and validating data and studies that made this landmark step forward possible
C-Path Announces FDA Commissioner Robert Califf to Participate in Opening Session at Inaugural Global Impact Conference
#CGIC24 Registration Nears Capacity; Closes Saturday, Aug. 31Continue reading
C-Path Awarded $1.5 Million Grant from Ara Parseghian Medical Research Fund at Notre Dame to Enhance Collaboration in Niemann-Pick Disease Research and Drug Development
TUCSON, Ariz., August 22, 2024 — Critical Path Institute (C-Path) is thrilled to announce its Critical Path for Lysosomal Diseases (CPLD) Consortium has been awarded a grant from the Ara Parseghian Medical Research Fund (APMRF) at the University of Notre Dame.Continue reading
C-Path’s TRxA Announces $250,000 Grant for Drug Development Project in Prostate Cancer
TUCSON, Ariz., August 22, 2024 – Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award to Peter Wipf, Ph.D., a distinguished researcher and professor at the University of Pittsburgh, Department of ChemistryContinue reading